from youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, IN THE SPIRIT OF WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, IN THE SPIRIT OF WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., IN THE SPIRIT OF RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
DEA QUOTAS
The DEA, in addition to enforcement, outlines administrative actions such as the proposed 2026 production quotas for all types of prescription opioids used medically, allocated to individual manufacturers, and supports successful community programs like the National Prescription Drug Take Back Day.
The newsletter from the DEA Diversion Control Division provides a comprehensive update on the agency’s efforts in late 2025 to fight the synthetic opioid crisis and regulate pharmaceutical distribution. The document emphasizes the rollout of the “Fentanyl Free America” campaign, highlighting significant drug seizures and offering educational tools to help the public identify clandestine digital communication, such as drug-related emojis.
This article’s presentation presumes that a federal agency can accurately predict how many specific formulations of opioids are necessary to serve a population of 330 million people in hospital and nonhospital settings in the coming year.
The agency has reduced these quotas since 2016, announcing in late 2019 plans to reduce the production of opioids to 53 percent of 2016 levels.
THE DANGERS OF OPIOID TAPERING
As pointed out by authors such as Richard Lawhern, Josh Bloom, Jeff Singer, et al., in 2016, the CDC issued its Guidelines for Prescribing Opioids for Chronic Pain Patients. In publishing these guidelines, the CDC explicitly stated that they were meant to be voluntary and “not prescriptive,” stating that healthcare practitioners knew their patients’ unique clinical situation and should weigh the potential risks and benefits when prescribing opioids.
Many of its recommendations were based on what the CDC characterized as “Type 3” or “Type 4” evidence, which are categories of less probative evidence with a significant risk of inaccuracy.
The guidelines thus came under significant criticism from many pain and addiction specialists for lacking a strong basis in the evidence.
Others criticized the use of morphine milligram equivalents (MMEs) in determining the appropriate dosing of different opioids. As Fudin and others have argued, MME dosing was designed in an attempt to examine opioids with similar analgesic effects and should not be used to determine an exact mathematical dosing conversion.
THE MYTH OF MORPHINE MILLIGRAM EQUIVALENT DAILY DOSE
The pharmacology and unique properties of each opioid and patient individuality must be considered when a therapeutic opioid conversion is contemplated. Conversion should not simply rely on a mathematical formula embedded within the CDC calc
🔓 🔓 🔓
ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!
OUR TREE OF KNOWLEDGE SHALL NEVER BE SUPPRESSED
FOR NOW, YOU ARE WITHIN
THE NORMS
